Al-Dhalimi MA, Al-Janabi MH. Split lesion randomized comparative study between long pulsed Nd:YAG laser 532 and 1,064 nm in treatment of facial port-wine stain. Lasers Surg Med. 2016;48(9):852–8.
Chen JK, Ghasri P, Aguilar G, Drooge AMv, Wolkerstorfer A, Kelly KM, et al. An overview of clinical and experimental treatment modalities for port wine stains. J Am Acad Dermatol. 2012;67(2):289–304.
Article PubMed PubMed Central Google Scholar
Horbach SER, Rigter IM, Smitt JHS, Reekers JA, Spuls PI, Horst CMAMvd. Intralesional bleomycin injections for vascular malformations: a systematic review and meta-analysis. Plastic Reconstr Surg. 2016;137(1):244–56.
Lokhorst MM, Jolink F, Horbach SER, Spuls PI, Horst CMAMvd. Surgical treatment of peripheral vascular malformations: a systematic review and meta-analysis. Plastic Reconstr Surg. 2021;147(5):1149–61.
Adams DM, Trenor CC, Hammill AM, Vinks AA, Patel MN, Chaudry G, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2): e20153257.
Article PubMed PubMed Central Google Scholar
Triana P, Dore M, Cerezo VN, Cervantes M, Sánchez AV, Ferrero MM, et al. Sirolimus in the treatment of vascular anomalies. Eur J Pediatr Surg. 2017;27(1):86–90.
Harbers VEM, Rongen GAPJM, Vleuten CJMvD, Verhoeven BH, Laat PCJd, Horst CM, et al. Patients with congenital low-flow vascular malformation treated with low dose sirolimus. Adv Therapy. 2021;38(6):3465–82.
Freixo C, Ferreira V, Martins J, Almeida R, Caldeira D, Rosa M, et al. Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review. J Vasc Surg. 2020;71(1):318–27.
Bevacqua M, Baldo F, Pastore S, Valencic E, Tommasini A, Maestro A, et al. Off-label use of sirolimus and everolimus in a pediatric center: a case series and review of the literature. Paediatr Drugs. 2019;21(3):185–93.
Article PubMed CAS Google Scholar
Zhang Z, Li Y, Zhang G, Yang K, Qiu T, Zhou J, et al. Safety evaluation of oral sirolimus in the treatment of childhood diseases: a systematic review. Children (Basel, Switzerland). 2022;9(9):1925.
Li H, Ji J, Du Y, Huang Y, Gu H, Chen M, et al. Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study. Exp Hematol. 2020;89:87–95.
Article PubMed CAS Google Scholar
Hicks CL, Baeyer CLV, Spafford PA, Korlaar Iv, Goodenough B. The Faces Pain Scale-revised: toward a common metric in pediatric pain measurement. Pain. 2001;93(2):173–83.
Li W, Qing Z, Jun C, Bifa F, Chongrong G, Li H, et al. Expert consensus on the application of pain evaluation questionnaires in China (2020). Chin J Painol. 2020;03:177–87.
Shirazi F, Cohen C, Fried L, Arbiser JL. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol. 2007;5(4):233–6.
Article PubMed CAS Google Scholar
Sebold AJ, Day AM, Ewen J, Adamek J, Byars A, Cohen B, et al. Sirolimus treatment in Sturge-Weber syndrome. Pediatr Neurol. 2021;115:29–40.
Ferreira J, Gutiérrez JCL, Carneiro A, Araújo A, Sousa PP, Braga S, et al. CLOVES syndrome diagnosis and treatment in an adult patient. Ann Vasc Surg. 2021;75:533.e5-e9.
Parker VER, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, Silva LD, et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genet Med. 2019;21(5):1189–98.
Article PubMed CAS Google Scholar
Filler G, Bendrick-Peart J, Christians U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit. 2008;30(2):138–42.
Article PubMed CAS Google Scholar
Rössler J, Baselga E, Davila V, Celis V, Diociaiuti A, Hachem ME, et al. Severe adverse events during sirolimus “off-label” therapy for vascular anomalies. Pediatr Blood Cancer. 2021;68(8): e28936.
Ji Y, Chen S, Yang K, Zhou J, Zhang X, Jiang X, et al. A prospective multicenter study of sirolimus for complicated vascular anomalies. J Vasc Surg. 2021;74(5):1673-81.e3.
Zúñiga-Castillo M, Teng CL, Teng JMC. Genetics of vascular malformation and therapeutic implications. Curr Opin Pediatr. 2019;31(4):498–508.
Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong J-P, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540–6.
Comments (0)